Your browser doesn't support javascript.
Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity.
Vono, Maria; Huttner, Angela; Lemeille, Sylvain; Martinez-Murillo, Paola; Meyer, Benjamin; Baggio, Stephanie; Sharma, Shilpee; Thiriard, Anais; Marchant, Arnaud; Godeke, Gert-Jan; Reusken, Chantal; Alvarez, Catia; Perez-Rodriguez, Francisco; Eckerle, Isabella; Kaiser, Laurent; Loevy, Natasha; Eberhardt, Christiane S; Blanchard-Rohner, Geraldine; Siegrist, Claire-Anne; Didierlaurent, Arnaud M.
  • Vono M; Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Huttner A; Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland; University of Geneva Medical School, Geneva, Switzerland; Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland; Center for Clinical Research, Ge
  • Lemeille S; Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Martinez-Murillo P; Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Meyer B; Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Baggio S; Division of Prison Health, Geneva University Hospitals, Geneva, Switzerland; Office of Corrections, Department of Justice and Home Affairs of the Canton of Zurich, Zurich, Switzerland.
  • Sharma S; Institute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium.
  • Thiriard A; Institute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium.
  • Marchant A; Institute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium.
  • Godeke GJ; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Reusken C; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Alvarez C; Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.
  • Perez-Rodriguez F; University of Geneva Medical School, Geneva, Switzerland; Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
  • Eckerle I; Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland; Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland; Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Swi
  • Kaiser L; Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland; Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland; Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Swi
  • Loevy N; Pediatric Platform for Clinical Research, Department of Woman, Child and Adolescent Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Eberhardt CS; Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Blanchard-Rohner G; Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Unit of Immunology and Vaccinology, Division of General Pediatrics, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals, University of Geneva, G
  • Siegrist CA; Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland; University of Geneva Medical School, Geneva, Switzerland.
  • Didierlaurent AM; Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland. Electronic address: arnaud.didierlaurent@unige.ch.
Cell Rep ; 37(1): 109773, 2021 10 05.
Article in English | MEDLINE | ID: covidwho-1442298
ABSTRACT
SARS-CoV-2 infection in children is less severe than it is in adults. We perform a longitudinal analysis of the early innate responses in children and adults with mild infection within household clusters. Children display fewer symptoms than adults do, despite similar initial viral load, and mount a robust anti-viral immune signature typical of the SARS-CoV-2 infection and characterized by early interferon gene responses; increases in cytokines, such as CXCL10 and GM-CSF; and changes in blood cell numbers. When compared with adults, the antiviral response resolves faster (within a week of symptoms), monocytes and dendritic cells are more transiently activated, and genes associated with B cell activation appear earlier in children. Nonetheless, these differences do not have major effects on the quality of SARS-CoV-2-specific antibody responses. Our findings reveal that better early control of inflammation as observed in children may be key for rapidly controlling infection and limiting the disease course.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cytokines / Transcriptome / SARS-CoV-2 / COVID-19 / Immunity, Innate / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Limits: Adolescent / Adult / Child / Child, preschool / Humans / Infant / Middle aged / Young adult Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2021.109773

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cytokines / Transcriptome / SARS-CoV-2 / COVID-19 / Immunity, Innate / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Limits: Adolescent / Adult / Child / Child, preschool / Humans / Infant / Middle aged / Young adult Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2021.109773